Table 1 Research investments in Norway in 2012 and the Norwegian and global burden of disease, measured by years of life lost (YLLs) and disability-adjusted life years (DALYs)
From: Are the Norwegian health research investments in line with the disease burden?
Percentage share of total research investments | Norway | Global | Rates | ||||||
|---|---|---|---|---|---|---|---|---|---|
Disease categories | RCN, NOK 783 mill. | RHAs, NOK 810 mill. | RCN + RHAs, NOK 1,593 mill. | % of YLLs | % of DALYs | % of YLLs | % of DALYs | Norway YLLs/Global YLLs | Norway DALYs/Global DALYs |
Musculoskeletal disorders | 2.0% | 4.3% | 3.2% | 0.6% | 17.0% | 0.2% | 6.5% | 2.00 | 2.6 |
Cancer | 15.5% | 23.1% | 19.4% | 32.8% | 15.5% | 10.7% | 7.6% | 1.78 | 2.0 |
Mental health | 12.0% | 12.8% | 12.4% | 3.8% | 15.6% | 0.5% | 7.4% | 3.26 | 2.1 |
Neurological disorders | 10.3% | 8.3% | 9.3% | 5.2% | 5.5% | 1.8% | 3.0% | 2.78 | 1.8 |
Metabolica | 3.1% | 4.1% | 3.6% | 2.6% | 3.8% | 2.0% | 2.3% | 0.86 | 1.6 |
Cardiovascular diseases | 7.1% | 13.0% | 10.1% | 27.9% | 14.4% | 15.9% | 11.5% | 1.27 | 1.3 |
Blood/urogenitalb | 0.4% | 2.55% | 1.48% | 1.6% | 2.70% | 1.9% | 2.52% | 1.06 | 1.1 |
Respiratory diseases | 1.4% | 0.9% | 1.2% | 5.3% | 5.0% | 4.0% | 4.8% | 0.89 | 1.1 |
Other nonc | 0.8% | 1.8% | 1.3% | 1.5% | 5.1% | 2.4% | 5.1% | 0.43 | 1.0 |
Oral and gastrointestinald | 1.2% | 2.0% | 1.6% | 3.1% | 1.8% | 3.4% | 2.6% | 0.81 | 0.7 |
Injuries | 0.6% | 0.4% | 0.5% | 10.0% | 8.9% | 13.5% | 11.1% | 0.59 | 0.8 |
Reproductive healthe | 2.9% | 3.5% | 3.2% | 1.6% | 0.9% | 12.2% | 8.9% | 0.05 | 0.1 |
Infection | 7.6% | 2.6% | 5.0% | 4.2% | 2.8% | 29.6% | 22.8% | 0.33 | 0.1 |
Correlation with the RCN investments | 0.59 | 0.51 | 0.19 | 0.24 | 0.63 | 0.41 | |||
Correlation with the RHAs investments | 0.80 | 0.67 | 0.05 | 0.04 | 0.57 | 0.53 | |||
Correlation with total investments (RCN + RHAs) | 0.73 | 0.62 | 0.11 | 0.12 | 0.61 | 0.49 | |||